KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Common Equity (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Common Equity for 16 consecutive years, with $48.8 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 86.58% to $48.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.8 million through Dec 2025, down 86.58% year-over-year, with the annual reading at $48.8 million for FY2025, 86.58% down from the prior year.
  • Common Equity for Q4 2025 was $48.8 million at Halozyme Therapeutics, down from $503.9 million in the prior quarter.
  • The five-year high for Common Equity was $503.9 million in Q3 2025, with the low at $48.8 million in Q4 2025.
  • Average Common Equity over 5 years is $234.4 million, with a median of $223.1 million recorded in 2021.
  • The sharpest move saw Common Equity surged 334.11% in 2024, then plummeted 86.58% in 2025.
  • Over 5 years, Common Equity stood at $197.0 million in 2021, then dropped by 13.79% to $169.8 million in 2022, then plummeted by 50.64% to $83.8 million in 2023, then soared by 334.11% to $363.8 million in 2024, then tumbled by 86.58% to $48.8 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $48.8 million, $503.9 million, and $332.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.